https://doi.org/10.55788/839e12e8
Dr Laia Oliveras (Hospital Universitari de Bellvitge, Spain) presented an analysis based on the European Renal Association Registry, including all patients who received a first kidney transplant between 2005 and 2022 in 12 European countries [1]. The maximum follow-up for each patient was 5 years, and diabetes was defined based on its classification as the primary cause of kidney failure. Mortality rates were standardised based on sex and age distributions to a normal population, and standardised mortality rate ratios (MRR) were used to compare the populations with and without diabetes.
A total of 134,231 individuals received a kidney transplant between 2005 and 2022, including 20,753 with diabetes. Overall, all-cause mortality rates tended to be stable between 2010 and 2019 and increased thereafter, both in patients with and without diabetes. The all-cause MRR between the two groups was 1.8. Similar trends were seen in cardiovascular mortality over time (MRR 2.3). A large component of all-cause mortality was driven by infection mortality, which markedly increased in both subgroups in the 2020-2022 period (overall infection-related MRR 1.6). Finally, cancer-related mortality remained stable over time, regardless of period, and the mortality was similar among the two subgroups (MRR 1.0).
“Kidney transplant recipients with diabetes had nearly two times higher mortality rates than those without diabetes, mainly due to cardiovascular and infection-related mortality”, concluded Dr Oliveras. However, “mortality rates for kidney transplant recipients remained stable from 2010 to 2019. During the COVID pandemic, both groups experienced an increase in infection-related mortality, when infection was the main cause of death.”
- Oliveras L, et al. Trends in all-cause and cause-specific mortality in adult first kidney transplant recipients with and without diabetes as cause of kidney failure: an ERA Registry study. 62nd ERA Congress, 4–7 June 2025, Vienna, Austria.
Posted on
Previous Article
« Dialysis initiation is associated with high rates of polypharmacy, which do not decrease over time Next Article
Different Alport Syndrome genotypes lead to different outcomes in terms of kidney function and mortality »
« Dialysis initiation is associated with high rates of polypharmacy, which do not decrease over time Next Article
Different Alport Syndrome genotypes lead to different outcomes in terms of kidney function and mortality »
Table of Contents: ERA 2025
Featured articles
Nefecon maintains kidney function regardless of baseline status over 24 months in IgA nephropathy
New Frontiers in Cardiorenal Protection: SGLT2 Inhibitors and Emerging Therapies
Acute eGFR dip following empagliflozin initiation is not associated with acute kidney injury
Sibeprenlimab is an emerging treatment option for IgA nephropathy
Finerenone plus empagliflozin as a new potential combination in patients with type 2 diabetes and chronic kidney disease
Large meta-analysis shows that empagliflozin slows kidney progression and reduces risk among patients with multiple diseases
Canagliflozin has a dose-dependent effect on cardiovascular outcomes in patients with type 2 diabetes
Late-Breaking Nephrology Studies
Survival benefit from kidney transplantation depends on the donor source
Mineral receptor antagonists are not beneficial for patients undergoing dialysis
Spironolactone is not useful in dialysis with cardiovascular risk
Factor XI inhibition is not useful for end-stage kidney disease patients receiving haemodialysis
ERA’s Top 10 Abstracts
Dialysis initiation is associated with high rates of polypharmacy, which do not decrease over time
NefIgArd: Nefecon leads to sustained decline in proteinuria and eGFR stabilisation
Immune checkpoint inhibitor-induced acute interstitial nephritis characterised by distinct immunophenotypes with potentially different management
Pegcetacoplan is a treatment option for patients with C3G or IC-MPGN with nephrotic-range proteinuria
Iptacopan improves mesenchymal and capillary glomerular C3 deposition in patients with C3 glomerulopathy
Ravulizumab improves long-term quality-of-life in atypical haemolytic uraemic syndrome
Lumasiran shows continued promise in infants and young children with primary hyperoxaluria type 1
Anti-PAPP-A antibody shows preclinical promise for autosomal dominant polycystic kidney disease
Nefecon maintains kidney function regardless of baseline status over 24 months in IgA nephropathy
Pegcetacoplan is a treatment option for adolescents with C3G or IC-MPGN
Clinical Outcomes in Transplant and Genetic Kidney Diseases
Different Alport Syndrome genotypes lead to different outcomes in terms of kidney function and mortality
Diabetes leads to negative mortality outcomes in kidney transplant patients
Emerging Pathophysiological Mechanisms and Therapeutic Targets
NPT2b could be a new therapeutic target for kidney diseases based on preclinical data
Inhibition of the cGAS/STING pathway has the potential to aid kidney recovery in chronic granulomatous disease
Related Articles
© 2024 Medicom Medical Publishers. All rights reserved. Terms and Conditions | Privacy Policy
HEAD OFFICE
Laarderhoogtweg 25
1101 EB Amsterdam
The Netherlands
T: +31 85 4012 560
E: publishers@medicom-publishers.com
